Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 23

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jun 21, 2022; 28(23): 2561-2568
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2561

Table 1 Considerations in initiating systemic therapy over transarterial chemoembolization[26,44,53-55]

No.	Considerations
1	Tumor exceeds “the up to seven" criteria
2	Tumor(s) larger than 5cm
3	Contiguous multinodular tumors
4	Poorly differentiated or undifferentiated HCC
5	No objective response to 2 consecvutive TACE treatments

HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization.

Citation: Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23): 2561-2568
URL: https://www.wjgnet.com/1007-9327/full/v28/i23/2561.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i23.2561

Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23): 2561-2568 [PMID: 35949352 DOI: 10.3748/wjg.v28.i23.2561]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.